Primary central nervous system lymphoma: Current state of anti-CD20 therapy and appraisal of reported response criteria

Journal of Clinical Neuroscience

Volumn 21, Issue 5, 2014, Pages 709-715

  Siegal, Tali ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

CD20 monoclonal antibodies; Cerebrospinal fluid; CNS lymphoma; Intra ocular lymphoma; Response criteria; Rituximab; Vitreous

Indexed keywords

CD20 ANTIBODY; METHOTREXATE; MICRORNA; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR MARKER; CD20 ANTIGEN;

B CELL LYMPHOMA; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CHILL; DRUG TOLERANCE; HUMAN; LUMBAR PUNCTURE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RIGOR; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR REGRESSION; ANIMAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; IMMUNOLOGY; LYMPHOMA, NON-HODGKIN; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; TREATMENT OUTCOME;

EID: 84898402281     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2014.02.002     Document Type: Review

References (65)

1. M. Preusser, A. Woehrer, and O. Koperek et al. Primary central nervous system lymphoma: a clinicopathological study of 75 cases Pathology 42 2010 547 552
2. A. Korfel, and U. Schlegel Diagnosis and treatment of primary CNS lymphoma Nat Rev Neurol 9 2013 317 327
3. M. Brainin, M. Barnes, and J.C. Baron et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces-revised recommendations 2004 Eur J Neurol 11 2004 577 581
4. W. Alduaij, and T.M. Illidge The future of anti-CD20 monoclonal antibodies: are we making progress? Blood 117 2011 2993 3001
5. M.M. Griffin, and N. Morley Rituximab in the treatment of non-Hodgkin's lymphoma-a critical evaluation of randomized controlled trials Expert Opin Biol Ther 13 2013 803 811
6. M.C. Chamberlain, and S.K. Johnston High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma Neuro Oncol 12 2010 736 744
7. A.J. Ferreri, S. Dell'Oro, and M. Foppoli et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas Neurology 66 2006 1435 1438
8. A.J. Ferreri, M. Reni, and M. Foppoli et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial Lancet 374 2009 1512 1520
9. G.D. Shah, J. Yahalom, and D.D. Correa et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma J Clin Oncol 25 2007 4730 4735
10. A. Omuro, L. Taillandier, and O. Chinot et al. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? J Neurooncol 104 2011 323 330
11. K. Jahnke, M. Hummel, and A. Korfel et al. Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes J Clin Oncol 24 2006 4754 4757
12. K.J. McCann, M. Ashton-Key, and K. Smith et al. Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development Blood 113 2009 4677 4680
13. J.L. Rubenstein, D. Combs, and J. Rosenberg et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment Blood 101 2003 466 468
14. J. Jin, K.M. Joo, and Y. Nam et al. Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system Exp Ther Med 1 2010 943 946
15. T.T. Batchelor, S.A. Grossman, and T. Mikkelsen et al. Rituximab monotherapy for patients with recurrent primary CNS lymphoma Neurology 76 2011 929 930
16. L.L. Muldoon, S.J. Lewin, and E. Dosa et al. Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma Clin Cancer Res 17 2011 2207 2215
17. T. Birnbaum, E.A. Stadler, and L. von Baumgarten et al. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma J Neurooncol 109 2012 285 291
18. K. Fritsch, B. Kasenda, and C. Hader et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly Ann Oncol 22 2011 2080 2085
19. G. Gregory, A. Arumugaswamy, and T. Leung et al. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma Neuro Oncol 15 8 2013 1068 1073
20. J.L. Rubenstein, E.D. Hsi, and J.L. Johnson et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) J Clin Oncol 31 25 2013 3061 3068
21. M.C. Chamberlain Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series J Neurooncol 113 2013 27 32
22. R.H. Enting, A. Demopoulos, and L.M. DeAngelis et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide Neurology 63 2004 901 903
23. S. Mappa, E. Marturano, and G. Licata et al. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy Hematol Oncol 31 3 2013 43 50
24. L. Nayak, L.E. Abrey, and J. Drappatz et al. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma Leuk Lymphoma 54 2013 58 61
25. E.T. Wong, R. Tishler, and L. Barron et al. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas Cancer 101 2004 139 145
26. F. Morschhauser, J. Radford, and A. Van Hoof et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma J Clin Oncol 26 2008 5156 5164
27. T.E. Witzig, L.I. Gordon, and F. Cabanillas et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol 20 2002 2453 2463
28. N.D. Doolittle, K. Jahnke, and R. Belanger et al. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma Leuk Lymphoma 48 2007 1712 1720
29. F.M. Iwamoto, J. Schwartz, and N. Pandit-Taskar et al. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma Cancer 110 2007 2528 2534
30. S. Maza, P. Kiewe, and D.L. Munz et al. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma Neuro Oncol 11 2009 423 429
31. E.T. Wong Management of central nervous system lymphomas using monoclonal antibodies: challenges and opportunities Clin Cancer Res 11 2005 7151s 7157s
32. J.L. Rubenstein, J. Fridlyand, and L. Abrey et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma J Clin Oncol 25 2007 1350 1356
33. J.L. Rubenstein, J. Li, and L. Chen et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma Blood 121 2013 745 751
34. G. Antonini, M.C. Cox, and E. Montefusco et al. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma J Neurooncol 81 2007 197 199
35. H. Pels, H. Schulz, and O. Manzke et al. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab J Neurooncol 59 2002 213 216
36. H. Schulz, H. Pels, and I. Schmidt-Wolf et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab Haematologica 89 2004 753 754
37. D.K. Bonney, E.E. Htwe, and A. Turner et al. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant Pediatr Blood Cancer 58 2012 459 461
38. K. Czyzewski, J. Styczynski, and A. Krenska et al. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder Leuk Lymphoma 54 2013 503 506
39. M.G. Kim, S.Y. Park, and E.J. Kim et al. Hepatitis B virus reactivation in a primary central nervous system lymphoma patient following intrathecal rituximab treatment Acta Haematol 125 2011 121 124
40. C.C. Chan, and H.N. Sen Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma Discov Med 15 2013 93 100
41. S.A. Grimm, C.A. McCannel, and A.M. Omuro et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report Neurology 71 2008 1355 1360
42. S.A. Grimm, J.S. Pulido, and K. Jahnke et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report Ann Oncol 18 2007 1851 1855
43. H. Kim, K.G. Csaky, and C.C. Chan et al. The pharmacokinetics of rituximab following an intravitreal injection Exp Eye Res 82 2006 760 766
44. A.S. Kitzmann, J.S. Pulido, and B.G. Mohney et al. Intraocular use of rituximab Eye (Lond) 21 2007 1524 1527
45. J.F. Mineo, A. Scheffer, and C. Karkoutly et al. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice Invest Ophthalmol Vis Sci 49 2008 4738 4745
46. K. Turaka, J.S. Bryan, and S. De Souza et al. Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution Clin Lymphoma Myeloma Leuk 12 2012 412 417
47. H. Raja, M.R. Snyder, and P.B. Johnston et al. Effect of intravitreal methotrexate and rituximab on interleukin-10 levels in aqueous humor of treated eyes with vitreoretinal lymphoma PLoS ONE 8 2013 e65627
48. N. Ohguro, N. Hashida, and Y. Tano Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma Arch Ophthalmol 126 2008 1002 1003
49. S. Itty, and J.S. Pulido Rituximab for intraocular lymphoma Retina 29 2009 129 132
50. L.E. Abrey, T.T. Batchelor, and A.J. Ferreri et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma J Clin Oncol 23 2005 5034 5043
51. W. Kuker, T. Nagele, and E. Thiel et al. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised Neurology 65 2005 1129 1131
52. H. Pels, A. Juergens, and I. Schirgens et al. Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma Neuro Oncol 12 2010 720 724
53. H. Ghesquieres, C. Ferlay, and C. Sebban et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Ann Oncol 21 2010 842 850
54. E. Thiel, A. Korfel, and P. Martus et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial Lancet Oncol 11 2010 1036 1047
55. A.J. Ferreri, G. Licata, and M. Foppoli et al. Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination Oncologist 16 2011 336 341
56. D.R. Macdonald, T.L. Cascino, and S.C. Schold Jr. et al. Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1990 1277 1280
57. H. Pels, A. Juergens, and A. Glasmacher et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study J Neurooncol 91 2009 299 305
58. N. Kawai, S. Okubo, and K. Miyake et al. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings Ann Nucl Med 24 2010 335 343
59. M.L. Lachenmayer, E. Blasius, and P. Niehusmann et al. Non-enhancing primary CNS lymphoma J Neurooncol 101 2011 343 344
60. A. Keswani, E. Bigio, and S. Grimm Lymphomatosis cerebri presenting with orthostatic hypotension, anorexia, and paraparesis J Neurooncol 109 2012 581 586
61. L. Fischer, A. Koch, and U. Schlegel et al. Non-enhancing relapse of a primary CNS lymphoma with multiple diffusion-restricted lesions J Neurooncol 102 2011 163 166
62. B.A. Carlson Rapidly progressive dementia caused by non-enhancing primary lymphoma of the central nervous system AJNR Am J Neuroradiol 17 1996 1695 1697
63. L.M. DeAngelis Cerebral lymphoma presenting as a non-enhancing lesion on computed tomographic/magnetic resonance scan Ann Neurol 33 1993 308 311
64. A. Baraniskin, J. Kuhnhenn, and U. Schlegel et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system Blood 117 2011 3140 3146
65. A. Baraniskin, J. Kuhnhenn, and U. Schlegel et al. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma J Neurooncol 109 2012 239 244